Abbvie Inc.

Deliang Zhou

Geoff G Z Zhang

Nathaniel Catron

Eric Allen Schmitt

Ping Tong

Yeshwant D Sanzgiri

Katherine R Heemstra

Cristina M Fischer

Anthony Ralph Haight

Rodger F Henry

Thomas B Borchardt

Paul J Brackemeyer

Xiaochun Lou

Michael G Fickes

Matthew M Ravn

A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

ABT-263 capsule

An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Stabilized lipid formulation of apoptosis promoter

ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Salt of ABT-263 and solid-state forms thereof

Growing community of inventors

Vernon Hills, IL, United States of America

Deliang Zhou